Tax
Deferred Foreign Tax Expense (Benefit)
Vertex Pharmaceuticals Deferred Foreign Tax Expense (Benefit) remained flat by 0.0% to $9.58M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 72.4%, from $34.65M to $9.58M. Over 2 years (FY 2023 to FY 2025), Deferred Foreign Tax Expense (Benefit) shows a downward trend with a -16.8% CAGR.
Analysis
StatementIncome Statement
SectionTax
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
glw_deferred_foreign_taxHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $55.30M | $138.60M | $38.30M |
| YoY Change | — | +150.6% | -72.4% |
Range$38.30M – $138.60M
CAGR-16.8%
Avg YoY Growth+39.1%
Median YoY Growth+39.1%
Deferred Foreign Tax Expense (Benefit) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's deferred foreign tax expense (benefit)?
- Vertex Pharmaceuticals (VRTX) reported deferred foreign tax expense (benefit) of $9.58M in Q4 2025.
- How has Vertex Pharmaceuticals's deferred foreign tax expense (benefit) changed year-over-year?
- Vertex Pharmaceuticals's deferred foreign tax expense (benefit) decreased by 72.4% year-over-year, from $34.65M to $9.58M.
- What is the long-term trend for Vertex Pharmaceuticals's deferred foreign tax expense (benefit)?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred foreign tax expense (benefit) has grown at a -16.8% compound annual growth rate (CAGR), from $55.30M to $38.30M.